BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

710 related articles for article (PubMed ID: 18157010)

  • 1. CpG therapy is superior to BCG in an orthotopic bladder cancer model and generates CD4+ T-cell immunity.
    Mangsbo SM; Ninalga C; Essand M; Loskog A; Tötterman TH
    J Immunother; 2008 Jan; 31(1):34-42. PubMed ID: 18157010
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.
    Mangsbo SM; Sandin LC; Anger K; Korman AJ; Loskog A; Tötterman TH
    J Immunother; 2010 Apr; 33(3):225-35. PubMed ID: 20445343
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of acetylic salicylic acid and pentoxifylline on the efficacy of intravesical BCG therapy in orthotopic murine bladder cancer (MB49).
    Günther JH; Frambach M; Deinert I; Brandau S; Jocham D; Böhle A
    J Urol; 1999 May; 161(5):1702-6. PubMed ID: 10210443
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Significance of target cell infection and natural killer cells in the anti-tumor effects of bacillus Calmette-Guerin in murine bladder cancer.
    Sonoda T; Sugimura K; Ikemoto S; Kawashima H; Nakatani T
    Oncol Rep; 2007 Jun; 17(6):1469-74. PubMed ID: 17487406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Genetically regulated response to intravesical bacillus Calmette Guerin immunotherapy of orthotopic murine bladder tumor.
    Kadhim SA; Chin JL; Batislam E; Karlik SJ; Garcia B; Skamene E
    J Urol; 1997 Aug; 158(2):646-52. PubMed ID: 9224385
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-12 immunotherapy of murine transitional cell carcinoma of the bladder: dose dependent tumor eradication and generation of protective immunity.
    O'Donnell MA; Luo Y; Hunter SE; Chen X; Hayes LL; Clinton SK
    J Urol; 2004 Mar; 171(3):1330-5. PubMed ID: 14767343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo vaccination with tumor cell lysate plus CpG oligodeoxynucleotides eradicates murine glioblastoma.
    Wu A; Oh S; Gharagozlou S; Vedi RN; Ericson K; Low WC; Chen W; Ohlfest JR
    J Immunother; 2007; 30(8):789-97. PubMed ID: 18049330
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cytokine gene expression in a mouse model: the first instillations with viable bacillus Calmette-Guerin determine the succeeding Th1 response.
    De Boer EC; Rooijakkers SJ; Schamhart DH; Kurth KH
    J Urol; 2003 Nov; 170(5):2004-8. PubMed ID: 14532842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses.
    Suttmann H; Riemensberger J; Bentien G; Schmaltz D; Stöckle M; Jocham D; Böhle A; Brandau S
    Cancer Res; 2006 Aug; 66(16):8250-7. PubMed ID: 16912205
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo effects of CpG-Oligodeoxynucleotides (CpG-ODN) on murine transitional cell carcinoma and on the native murine urinary bladder wall.
    Olbert PJ; Schrader AJ; Simon C; Dalpke A; Barth P; Hofmann R; Hegele A
    Anticancer Res; 2009 Jun; 29(6):2067-76. PubMed ID: 19528466
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of bacillus Calmette-Guérin-induced nitric oxide in bladder tumor cells may improve BCG treatment.
    Alvarez V; Lodillinsky C; Umerez S; Sandes E; Eiján AM
    Int J Mol Med; 2005 Oct; 16(4):565-71. PubMed ID: 16142388
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Changes in mucosal immune cells of bladder tumor patient after BCG intravesical immunotherapy.
    Chang SG; Lee SJ; Huh JS; Lee JH
    Oncol Rep; 2001; 8(2):257-61. PubMed ID: 11182036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimizing syngeneic orthotopic murine bladder cancer (MB49).
    Günther JH; Jurczok A; Wulf T; Brandau S; Deinert I; Jocham D; Böhle A
    Cancer Res; 1999 Jun; 59(12):2834-7. PubMed ID: 10383142
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enhancement of immunologic tumor regression by intratumoral administration of dendritic cells in combination with cryoablative tumor pretreatment and Bacillus Calmette-Guerin cell wall skeleton stimulation.
    Udagawa M; Kudo-Saito C; Hasegawa G; Yano K; Yamamoto A; Yaguchi M; Toda M; Azuma I; Iwai T; Kawakami Y
    Clin Cancer Res; 2006 Dec; 12(24):7465-75. PubMed ID: 17189420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunodominant PstS1 antigen of mycobacterium tuberculosis is a potent biological response modifier for the treatment of bladder cancer.
    Sänger C; Busche A; Bentien G; Spallek R; Jonas F; Böhle A; Singh M; Brandau S
    BMC Cancer; 2004 Nov; 4():86. PubMed ID: 15566565
    [TBL] [Abstract][Full Text] [Related]  

  • 16. AdCD40L gene therapy counteracts T regulatory cells and cures aggressive tumors in an orthotopic bladder cancer model.
    Loskog AS; Fransson ME; Totterman TT
    Clin Cancer Res; 2005 Dec; 11(24 Pt 1):8816-21. PubMed ID: 16361570
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intravesical interleukin-12 gene therapy in an orthotopic bladder cancer model.
    Horinaga M; Harsch KM; Fukuyama R; Heston W; Larchian W
    Urology; 2005 Aug; 66(2):461-6. PubMed ID: 16040105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MB49 murine urothelial carcinoma: molecular and phenotypic comparison to human cell lines as a model of the direct tumor response to bacillus Calmette-Guerin.
    Chen F; Zhang G; Cao Y; Hessner MJ; See WA
    J Urol; 2009 Dec; 182(6):2932-7. PubMed ID: 19853870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antineoplastic effect of immunostimulatory DNA (CpG-ODN) in a murine C57-BL6/MB-49 transitional cell carcinoma model.
    Hegele A; Dalpke A; Barth P; Varga Z; Heeg K; Hofmann R; Olbert P
    Anticancer Res; 2004; 24(4):2225-30. PubMed ID: 15330165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. CpG oligonucleotide therapy cures subcutaneous and orthotopic tumors and evokes protective immunity in murine bladder cancer.
    Ninalga C; Loskog A; Klevenfeldt M; Essand M; Tötterman TH
    J Immunother; 2005; 28(1):20-7. PubMed ID: 15614041
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.